Vivos Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $6.0M
- Price
- $0.297
- % Change (Daily % change from the live per-ticker quote feed.)
- +6.41%
- Volume
- 122.8K
About
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
Quick stats
Shares outstanding13.9M
Computed float13.8M
Float / shares99.4%
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001716166
Websitehttps://www.vivos.com
AI Summary
AI-generated1/22
standardbullishoperations update
Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment
Vivos Therapeutics opened a new diagnostic and treatment facility in Henderson, Nevada, expanding its Sleep Centers of Nevada network.
The company expects the location to more than double annual revenue production capacity in the area to over $10 million, supported by a recent doubling of patient referrals in the Las Vegas market.
The center offers integrated services including FDA-cleared oral appliance therapy, laser therapy, and diagnostics, and is expected to employ up to 30 personnel at full capacity.
Red flags
- Company disclosed risk that it may be unable to secure additional financing to maintain its Nasdaq listing
- Reliance on forward-looking statements regarding facility performance and recruitment of qualified personnel